Wave Life Sciences Ltd. Ordinary Shares (WVE) Stock Price

WVEStock

$3.13−60.23%52W

Market Cap$616.76M

P/E—

PEG Ratio—

Div yield—

Beta-1.48

WVE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-67.55%

Price vs S&P 500 (4W)-25.11%

VGM Score38.28

Book Value / Share (Quarterly)$2.35

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)127.06%

Cash Flow / Share (Quarterly)$-1.00

Price vs S&P 500 (YTD)-93.51%

Net Profit Margin (TTM)-309.73%

EPS (TTM)$-1.09

10-Day Avg Trading Volume3.02M

EPS Excl Extra (TTM)$-1.09

Revenue Growth (5Y)16.30%

EPS (Annual)$-1.21

ROI (Annual)-38.84%

Net Profit Margin (5Y Avg)-1070.11%

Cash / Share (Quarterly)$2.54

Revenue Growth QoQ (YoY)-73.88%

ROA (Last FY)-32.01%

Revenue Growth TTM (YoY)-30.42%

EBITD / Share (TTM)$-1.14

ROE (5Y Avg)-134.48%

Operating Margin (TTM)-333.36%

Cash Flow / Share (Annual)$-1.00

P/B Ratio1.40x

P/B Ratio (Quarterly)2.46x

Net Income / Employee (Annual)$-644,700

EV / Revenue (TTM)4.08x

ROA (TTM)-40.06%

EPS Incl Extra (Annual)$-1.21

Current Ratio (Annual)6.47x

Quick Ratio (Quarterly)9.75x

3-Month Avg Trading Volume3.14M

52-Week Price Return-60.23%

Revenue / Employee (TTM)$206,200

Tangible BV / Share (Quarterly)$-0.33

P/S Ratio (Annual)14.85x

Asset Turnover (Annual)0.07x

52-Week High$21.73

Operating Margin (5Y Avg)-1086.85%

EPS Excl Extra (Annual)$-1.21

CapEx CAGR (5Y)-11.73%

26-Week Price Return-57.65%

Quick Ratio (Annual)6.38x

13-Week Price Return-46.22%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)9.99x

Enterprise Value$266.48M

Revenue / Share Growth (5Y)-13.13%

Asset Turnover (TTM)0.13x

Book Value / Share Growth (5Y)6.05%

Revenue / Employee (Annual)$134,800

Pretax Margin (Annual)-478.33%

Cash / Share (Annual)$3.21

3-Month Return Std Dev55.12%

Net Income / Employee (TTM)$-638,700

ROE (Last FY)-38.84%

EPS Basic Excl Extra (Annual)$-1.21

Receivables Turnover (TTM)52.19x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.09

Receivables Turnover (Annual)31.67x

ROI (TTM)-49.87%

P/S Ratio (TTM)9.71x

Pretax Margin (5Y Avg)-1066.60%

Revenue / Share (Annual)$0.25

Tangible BV / Share (Annual)$-0.43

Price vs S&P 500 (52W)-75.76%

Year-to-Date Return-81.59%

5-Day Price Return-4.57%

EPS Normalized (Annual)$-1.21

ROA (5Y Avg)-50.01%

Net Profit Margin (Annual)-478.33%

Month-to-Date Return-15.41%

Cash Flow / Share (TTM)$-0.78

EBITD / Share (Annual)$-1.26

Operating Margin (Annual)-504.09%

ROI (5Y Avg)-134.48%

EPS Basic Excl Extra (TTM)$-1.09

P/B Ratio (Annual)5.91x

Pretax Margin (TTM)-309.73%

Book Value / Share (Annual)$2.80

Price vs S&P 500 (13W)-48.91%

Beta-1.48x

Revenue / Share (TTM)$0.32

ROE (TTM)-49.87%

52-Week Low$3.04

vGradeC

gGradeD

mGradeD

vgmGradeD

WVE Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 30, 2026	-$0.30	-$0.34	-14.40%(-$0.04)
Q1 2026	Apr 28, 2026	-$0.31	-$0.13	+58.51%(+$0.18)
Q4 2025	Feb 26, 2026	-$0.26	-$0.30	-13.50%(-$0.04)
Q3 2025	Nov 10, 2025	-$0.30	-$0.32	-8.18%(-$0.02)
Q2 2025	Jul 30, 2025	-$0.28	-$0.31	-9.02%(-$0.03)

WVE Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.25

4.29

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
WVEWave Life Sciences Ltd. Ordinary Shares	C	D	D	9.7x	-30.4%	—	—	$3.13
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Wave Life Sciences Ltd. Ordinary Shares

WAVE Life Sciences is a clinical-stage biotech company developing RNA medicines to treat rare and prevalent diseases using its proprietary PRISM platform. The platform combines multiple RNA-targeting modalities—RNA editing, antisense silencing, and RNA interference—with chemistry innovation and genetic insights to optimize drug design and delivery. WAVE's pipeline targets major market opportunities including obesity, Duchenne muscular dystrophy, Huntington's disease, and alpha-1 antitrypsin deficiency.

WVE Next Earnings Report

Report dateNov 9, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate-$0.32

Revenue estimate$4.51M

Also reporting on Nov 9, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

WVE Insider Transactions

SellAug 12, 2026
RAWCLIFFE ADRIAN
Director
Shares: 12,700Value: $67,183
SellAug 11, 2026
WAGNER HEIDI L
Director
Shares: 7,000Value: $42,070
SellAug 11, 2026
TAKANASHI KEN
Director
Shares: 3,864Value: $23,223
SellAug 11, 2026
TAN AIK NA
Director
Shares: 432Value: $2,596

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

PRMEPrime Medicine, Inc. Common StockBiological Products
ATTOAttovia Therapeutics, Inc. Common StockBiological Products
CADLCandel Therapeutics, Inc. Common StockBiological Products
PCTPureCycle Technologies, Inc. Common stockPlastics & Resins
SLDBSolid Biosciences Inc. Common StockBiological Products
DBVTDBV Technologies S.A. American Depositary SharesBiological Products
TROXTRONOX LIMITED CL A ORDINARY SHARESIndustrial Chemicals
ETRAElectra Therapeutics, Inc. Common stockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$3.04

High$21.73